[
  {
    "ts": "2025-12-11T05:10:38+00:00",
    "headline": "Did Eli Lilly's (LLY) US$6 Billion Alabama Bet on Orforglipron Just Shift Its Investment Narrative?",
    "summary": "Eli Lilly and Company recently announced plans to invest more than US$6.00 billion in a new Huntsville, Alabama API facility that will produce small‑molecule and peptide medicines, including its oral GLP‑1 obesity candidate orforglipron, with construction slated to begin in 2026 and completion targeted for 2032. Alongside this large U.S. manufacturing build‑out, Lilly is advancing Jaypirca in leukemia with Phase 3 data and expanded FDA approval, underscoring how obesity and oncology...",
    "url": "https://finance.yahoo.com/news/did-eli-lillys-lly-us-051038418.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "280a4dfc-8c44-3217-a112-317e692ac122",
      "content": {
        "id": "280a4dfc-8c44-3217-a112-317e692ac122",
        "contentType": "STORY",
        "title": "Did Eli Lilly's (LLY) US$6 Billion Alabama Bet on Orforglipron Just Shift Its Investment Narrative?",
        "description": "",
        "summary": "Eli Lilly and Company recently announced plans to invest more than US$6.00 billion in a new Huntsville, Alabama API facility that will produce small‑molecule and peptide medicines, including its oral GLP‑1 obesity candidate orforglipron, with construction slated to begin in 2026 and completion targeted for 2032. Alongside this large U.S. manufacturing build‑out, Lilly is advancing Jaypirca in leukemia with Phase 3 data and expanded FDA approval, underscoring how obesity and oncology...",
        "pubDate": "2025-12-11T05:10:38Z",
        "displayTime": "2025-12-11T05:10:38Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uZWvuDuy6_Wr6cKvxAFZcw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g78F5NO5pySOmBHzFi6.eA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/did-eli-lillys-lly-us-051038418.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/did-eli-lillys-lly-us-051038418.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-11T07:00:00+00:00",
    "headline": "Microsoft, Broadcom, Lilly, and Other Stocks That Meet This Pro’s Definition of ‘Quality’",
    "summary": "Tom Hancock, a portfolio manager at GMO, favors companies that consistently earn a high return on capital and reinvest in the business.",
    "url": "https://www.barrons.com/articles/microsoft-broadcom-lilly-stocks-f036c3cc?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "2da8b293-1ab5-34e6-8cef-c1d728ca2038",
      "content": {
        "id": "2da8b293-1ab5-34e6-8cef-c1d728ca2038",
        "contentType": "STORY",
        "title": "Microsoft, Broadcom, Lilly, and Other Stocks That Meet This Pro’s Definition of ‘Quality’",
        "description": "",
        "summary": "Tom Hancock, a portfolio manager at GMO, favors companies that consistently earn a high return on capital and reinvest in the business.",
        "pubDate": "2025-12-11T07:00:00Z",
        "displayTime": "2025-12-11T07:00:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/2da8b293-1ab5-34e6-8cef-c1d728ca2038/microsoft-broadcom-lilly-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/343e152b8141ff37e2072d778b84cfd1",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Hy6O0hbzpqCmO0W7v8y2Rg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/343e152b8141ff37e2072d778b84cfd1.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hb0p.6Z7.pB7JoES9lq54Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/343e152b8141ff37e2072d778b84cfd1.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/microsoft-broadcom-lilly-stocks-f036c3cc?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MSFT"
            },
            {
              "symbol": "AVGO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-11T07:52:25+00:00",
    "headline": "Eli Lilly’s Mounjaro Added to China’s National Health Insurance for Diabetes",
    "summary": "Eli Lilly and Company (NYSE:LLY) is included among the 15 Best Stocks to Buy for the Long Term. Eli Lilly and Company (NYSE:LLY)’s popular drug Mounjaro will be added to China’s state-run health insurance program starting January 1, the National Healthcare Security Administration said in a notice on December 8. Analysts say that the move […]",
    "url": "https://finance.yahoo.com/news/eli-lilly-mounjaro-added-china-075225117.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "460f09e2-4a74-31cd-a6cd-2de0478c6595",
      "content": {
        "id": "460f09e2-4a74-31cd-a6cd-2de0478c6595",
        "contentType": "STORY",
        "title": "Eli Lilly’s Mounjaro Added to China’s National Health Insurance for Diabetes",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE:LLY) is included among the 15 Best Stocks to Buy for the Long Term. Eli Lilly and Company (NYSE:LLY)’s popular drug Mounjaro will be added to China’s state-run health insurance program starting January 1, the National Healthcare Security Administration said in a notice on December 8. Analysts say that the move […]",
        "pubDate": "2025-12-11T07:52:25Z",
        "displayTime": "2025-12-11T07:52:25Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Eli Lilly’s Mounjaro Added to China’s National Health Insurance for Diabetes",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6aY42asq7dEA24eM0JX3IQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8359URliL1_uJRGx4OlSUg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-mounjaro-added-china-075225117.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-mounjaro-added-china-075225117.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-11T06:15:00+00:00",
    "headline": "Novo Nordisk Is Trading as If Obesity Drug Craze Never Happened",
    "summary": "The slump has virtually wiped out several years of stellar gains that came after Novo’s Wegovy drug was approved as a weight-loss treatment in 2021.  “When I look at it right now, organically, their pipeline doesn’t convince me that this situation is manageable,” said Paul Major, a portfolio manager at Bellevue Asset Management.  Novo bulls are hoping that pending approvals of a higher-dose Wegovy shot and an oral version of the drug will turn things around and boost the company’s position against rival Eli Lilly & Co. Novo has sought approval of the stronger injectable version of Wegovy in the US under a priority voucher, which will speed review.",
    "url": "https://finance.yahoo.com/news/novo-nordisk-trading-obesity-drug-061500298.html",
    "source": "Bloomberg",
    "provider": "yfinance",
    "raw": {
      "id": "1ca66d58-8013-3e8b-8914-b38a062a9450",
      "content": {
        "id": "1ca66d58-8013-3e8b-8914-b38a062a9450",
        "contentType": "STORY",
        "title": "Novo Nordisk Is Trading as If Obesity Drug Craze Never Happened",
        "description": "",
        "summary": "The slump has virtually wiped out several years of stellar gains that came after Novo’s Wegovy drug was approved as a weight-loss treatment in 2021.  “When I look at it right now, organically, their pipeline doesn’t convince me that this situation is manageable,” said Paul Major, a portfolio manager at Bellevue Asset Management.  Novo bulls are hoping that pending approvals of a higher-dose Wegovy shot and an oral version of the drug will turn things around and boost the company’s position against rival Eli Lilly & Co. Novo has sought approval of the stronger injectable version of Wegovy in the US under a priority voucher, which will speed review.",
        "pubDate": "2025-12-11T06:15:00Z",
        "displayTime": "2025-12-11T06:15:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2025-12/03d1cb40-d66f-11f0-bdfb-ee6487c841eb",
          "originalWidth": 5086,
          "originalHeight": 3391,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/aZoqsZiNz1K4FmBk81kNFg--~B/aD0zMzkxO3c9NTA4NjthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2025-12/03d1cb40-d66f-11f0-bdfb-ee6487c841eb.cf.webp",
              "width": 5086,
              "height": 3391,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/LuK9B6s8jPY9CaBFC6_eYA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2025-12/03d1cb40-d66f-11f0-bdfb-ee6487c841eb.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Bloomberg",
          "url": "https://www.bloomberg.com/company"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-trading-obesity-drug-061500298.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-trading-obesity-drug-061500298.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "ZLDPF"
            },
            {
              "symbol": "HIMS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]